ES2196864T3 - Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1. - Google Patents

Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.

Info

Publication number
ES2196864T3
ES2196864T3 ES99948807T ES99948807T ES2196864T3 ES 2196864 T3 ES2196864 T3 ES 2196864T3 ES 99948807 T ES99948807 T ES 99948807T ES 99948807 T ES99948807 T ES 99948807T ES 2196864 T3 ES2196864 T3 ES 2196864T3
Authority
ES
Spain
Prior art keywords
nucleic acids
antisense nucleic
expression
icam
adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99948807T
Other languages
English (en)
Inventor
Volker Patzel
Ralf Kronenwett
Ulrich Steidl
Rainer Haas
Georg Sczakiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19844111A external-priority patent/DE19844111A1/de
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2196864T3 publication Critical patent/ES2196864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Acido nucleico antisentido, que está dirigido por ICAM-1 contra una secuencia específica de ácidos nucleicos y que consta como mínimo de una de las secuencias de ácidos nucleicos caracterizadas por al menos una de SEC ID N° 1-12, 15, 29 y 30.
ES99948807T 1998-09-25 1999-09-21 Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1. Expired - Lifetime ES2196864T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19844111A DE19844111A1 (de) 1998-09-25 1998-09-25 Antisense-Sequenzen für die Hemmung der Expression des Adhäsionsmoleküls ICAM-1
DE19856138 1998-12-04
DE19926110 1999-06-08

Publications (1)

Publication Number Publication Date
ES2196864T3 true ES2196864T3 (es) 2003-12-16

Family

ID=27218700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99948807T Expired - Lifetime ES2196864T3 (es) 1998-09-25 1999-09-21 Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.

Country Status (6)

Country Link
EP (1) EP1115858B1 (es)
AT (1) ATE236250T1 (es)
AU (1) AU6193699A (es)
DE (1) DE59904870D1 (es)
ES (1) ES2196864T3 (es)
WO (1) WO2000018907A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109810A2 (en) * 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
GB201700261D0 (en) * 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New therapeutic uses
GB201700257D0 (en) 2017-01-06 2017-02-22 Atlantic Pharmaceuticals (Holdings) Ltd New formulation
CA3070958A1 (en) 2017-07-28 2019-01-31 Universitat Zu Lubeck Antisense drugs against canine icam-1 for use in the treatment of inflammation of the buccal cavity
EP3685824A1 (en) * 2019-01-25 2020-07-29 Breitenbronn-Consulting GbR Composition for administering and releasing oligonucleotides
CN113454220B (zh) * 2019-01-25 2024-08-23 吕贝克大学 针对人细胞间粘附分子1(icam-1)的反义药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005333A1 (en) * 1992-09-02 1994-03-17 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
ATE395418T1 (de) * 1994-04-13 2008-05-15 Biotransplant Inc Alpha(1,3)galactosyltransferase-negatives schwein
WO1998024797A1 (en) * 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules

Also Published As

Publication number Publication date
WO2000018907A2 (de) 2000-04-06
AU6193699A (en) 2000-04-17
EP1115858A2 (de) 2001-07-18
ATE236250T1 (de) 2003-04-15
WO2000018907A3 (de) 2000-06-29
DE59904870D1 (de) 2003-05-08
EP1115858B1 (de) 2003-04-02

Similar Documents

Publication Publication Date Title
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
PT980263E (pt) Produto de combinacao que associa um acido nucleico a uma substancia desorganizadora da matriz extracelular para terapia genetica
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
DE69736432D1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
AU9016998A (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
PT973794E (pt) Receptores de netrina
BR9813917A (pt) Vetores de expressão induzìveis hipertérmicospara terapia de genetica e métodos de uso dos mesmos
Schmitz et al. Hyaluronan oligosaccharide treatment of chondrocytes stimulates expression of both HAS-2 and MMP-3, but by different signaling pathways
Hanabayashi et al. Hyaluronan oligosaccharides induce MMP-1 and-3 via transcriptional activation of NF-κB and p38 MAPK in rheumatoid synovial fibroblasts
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ES2196864T3 (es) Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
Paas et al. Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells
AU4152799A (en) Glycoproteins having lipid mobilising properties and therapeutic applications thereof
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
Poirier et al. Proteomic analysis of a lymphoma‐derived cell line (DG75) following treatment with a demethylating drug: Modification of membrane‐associated proteins
Nakayama et al. Effects of porcine 25 kDa amelogenin and its proteolytic derivatives on bone sialoprotein expression
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
DE60044038D1 (de) Xylosyltransferase und isoformen
Miyata et al. Analysis of gene expression in homocysteine-injured vascular endothelial cells: demonstration of GRP78/BiP expression, cloning and characterization of a novel reducing agent-tunicamycin regulated gene